Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

5-phenylnicotinamide bcr-abl inhibitors as well as preparation method and application thereof

A technology of phenylnicotinamide and bcr-abl, which is applied in the field of biomedicine, can solve the problems of mutation resistance and drug resistance, and achieve the effect of cheap reagents, mild reaction conditions and easy availability of raw materials

Active Publication Date: 2015-01-07
XI AN JIAOTONG UNIV
View PDF3 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, a variety of small molecule inhibitors targeting BCR-ABL have emerged, but all of them have drug resistance problems. Therefore, Bcr-Abl mutation drug resistance is a major problem in this research field. The research and development of pharmaceutical agents has become one of the hot spots in the field of pharmacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 5-phenylnicotinamide bcr-abl inhibitors as well as preparation method and application thereof
  • 5-phenylnicotinamide bcr-abl inhibitors as well as preparation method and application thereof
  • 5-phenylnicotinamide bcr-abl inhibitors as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] In the structural formula of 5-phenylnicotinamide Bcr-Abl inhibitors, R 1 is morpholinyl, R 2 For m-trifluoromethyl, prepared by the following steps:

[0043] 1) Preparation of p-carboxyphenylboronic acid (compound 4)

[0044] Add treated Mg strips (2.15g, 90mmol), 2 capsules of iodine into a 250ml double-necked bottle, protect with nitrogen, and vacuumize 3 times. Slowly add the anhydrous THF solution of the compound p-methylbromobenzene (compound 1, 60mmol) with a syringe under heating conditions. After the reaction is initiated, it is in a reflux state. Continue to add the remaining solution. After the addition, reflux for 5 hours to obtain the format of p-bromotoluene Reagent (compound 2), after cooling to room temperature, the reaction device was transferred to a low-temperature reactor, and the temperature was adjusted to -20 ° C. After 5 minutes, anhydrous THF solution of trimethyl borate (9.36 g, 90 mmol) was added with a syringe, After the addition, react at...

Embodiment 2

[0062] In the structural formula of the inhibitor, R 1 is cyclopropylamino, R 2 is 3,4-difluoro, prepared by the following steps:

[0063] Step 1) is the same as in Example 1, that is, p-carboxyphenylboronic acid (compound 4) is prepared from p-bromotoluene (compound 1).

[0064] 2) Preparation of 5-bromo-N-cyclopropylnicotinamide (compound 7)

[0065] Under the protection of nitrogen, 20ml of thionyl chloride was added dropwise to 5-bromonicotinic acid (compound 5, 5.0g, 24.7mmol). After the dropwise addition, reflux to clarification and react for 2 hours. After the reaction was completed, the pressure was reduced. Thionyl chloride was spin-off to obtain 5-bromonicotinoyl chloride (compound 6);

[0066] 5-Bromonicotinoyl chloride (compound 6) was dissolved in anhydrous dichloromethane (30ml), and the acid chloride solution was added dropwise to cyclopropylamine (3.77ml, 54.4mmol) in anhydrous dichloromethane ( 50ml) solution, after the dropwise addition, remove the ice ba...

Embodiment 3

[0080] In the structural formula of the inhibitor, R 1 is diisopropylamino, R 2 For m-dimethylamino, prepared by the following steps:

[0081] Step 1) is the same as step 1) in Example 1, that is, p-carboxyphenylboronic acid (compound 4) is prepared from p-bromotoluene (compound 1).

[0082] 2) Preparation of 5-bromo-N,N-diisopropylnicotinamide (compound 7)

[0083] Under the protection of nitrogen, 20ml of thionyl chloride was added dropwise to 5-bromonicotinic acid (compound 5, 5.0g, 24.7mmol). After the dropwise addition, reflux to clarification and react for 2 hours. After the reaction was completed, the pressure was reduced. Thionyl chloride was spin-off to obtain 5-bromonicotinoyl chloride (compound 6);

[0084] 5-Bromonicotinoyl chloride (compound 6) was dissolved in anhydrous dichloromethane (30ml), and the acid chloride solution was added dropwise to diisopropylamine (7.66ml, 54.4mmol) in anhydrous dichloromethane (30ml) in an ice bath. Chloromethane (50ml) soluti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses 5-phenylnicotinamide Bcr-Abl inhibitors as well as a preparation method and application thereof. A structural formula of the compounds is shown in the specification, wherein in the structural formula, R1 is morpholinyl, cyclopropylamino, diisopropylamino, diethylin, isopropylamino or an N,N-dimethylethylenediamine group; R2 is a mono-substituent or a di-substituent, and the substituent is tertiary amine or halogen. The series of inhibitors have a certain inhibiting effect on ABL1 kinase in vitro, can inhibit proliferation of a tumor cell K562 and can be used for preparing antitumor drugs, especially CML (chronic myelocytic leukemia) drugs. The preparation method of the 5-phenylnicotinamide Bcr-Abl inhibitors, which is provided by the invention, has the advantages of easiness in obtainment of raw materials, mild reaction conditions, simplicity in operation of reaction processes and cheap used reagents.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and relates to an antitumor compound, in particular to a 5-phenylnicotinamide Bcr-Abl inhibitor and a preparation method and application thereof. Background technique [0002] Chronic myelogenous leukemia (CML) is a hematological systemic clonal proliferative disease occurring in hematopoietic stem cells, and it is also the most common type of leukemia. In western countries, CML accounts for about 15-20% of adult leukemias, and can occur in all age groups, with middle-aged and elderly cases being the most common. CML is caused by the overexpressed Bcr-Abl protein of the breakpoint cluster region-Abelsonian leukemia virus (BCR-ABL) fusion gene formed by t(9;22)(q34;q11) chromosome translocation. At present, a variety of small-molecule inhibitors targeting BCR-ABL have emerged, but all of them have drug resistance problems. Therefore, Bcr-Abl mutation drug resistance is a major problem in this ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D213/82A61K31/496A61K31/5377A61P35/00A61P35/02
CPCC07D213/82
Inventor 张杰贺浪冲潘晓艳卢闻张涛王嗣岑董金云苏萍
Owner XI AN JIAOTONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com